Virtual Reality-Based Cognitive Remediation in Schizophrenia and Bipolar Disorder
FULL-MINDSET- Fully Immersive Virtual Reality-based Cognitive Training in Schizophrenia and Bipolar Disorder: a Single Blind Randomized Controlled Trial in a Real-world Setting
This randomized controlled trial aims to evaluate the effectiveness of a virtual reality-based cognitive remediation (VRCR) intervention in improving cognitive performance and psychosocial functioning in individuals with schizophrenia spectrum disorders (SSD) and bipolar disorder (BD).
A total of 80 participants (40 with SSD and 40 with BD) will be randomly assigned in a 1:1 ratio to receive either VRCR or treatment as usual (TAU). The VRCR intervention will be delivered using the CEREBRUM platform and will consist of 45-minute sessions administered twice weekly for 12 weeks under the supervision of trained therapists.
The primary outcomes are changes in cognitive performance and psychosocial functioning, assessed using the MATRICS Consensus Cognitive Battery (MCCB) and the Personal and Social Performance (PSP) scale, respectively. Secondary outcomes include clinical symptom severity, assessed with validated rating scales, and neurobiological correlates, including functional magnetic resonance imaging (fMRI) and genetic biomarkers.
Assessments will be conducted at baseline, at 3 months (post-intervention), and at 6 months (follow-up). fMRI assessments will be conducted at baseline in patients with schizophrenia spectrum disorders, whereas peripheral blood samples for genetic marker analyses will be collected at baseline and at the 3-month follow-up in patients with SSD and BD. This study is expected to provide evidence on the feasibility, acceptability, and effectiveness of VR-based cognitive remediation in SSD and BD, as well as insights into the neurobiological mechanisms underlying cognitive and functional improvements.
調査の概要
状態
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Lombardy
-
Brescia、Lombardy、イタリア、25123
- ASST Spedali Civili di Brescia - Department of Mental Health and Addiction Services
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Age ≥ 18 years
- Diagnosis of schizophrenia spectrum disorder or bipolar disorder (DSM-5)
- Clinical stability for at least 3 months
- Ability to provide informed consent
Exclusion Criteria:
- neurological disorders
- intellectual disability
- inability to participate in VR-based interventions due to medical or sensory limitations.
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：Participants with diagnosis of schizophrenia receiving VRCR
|
Participants in the VRCR group will receive individualized cognitive training using the CEREBRUM platform (IDEGO, Rome, Italy). CEREBRUM is an immersive virtual reality software where the user wearing the viewer sees a virtual environment that can be explored at 360°; it consists of 52 ecologically valid exercises of varying difficulty: 22 belonging to the Memory, and Learning Module, 10 to the Cognitive Estimates Module and 20 to the Attention and Working Memory Module. The difficulty of exercises is adaptable to provide adequately implement scaffolding and errorless learning principles, and the exercises require active interaction with the therapist. The software is compatible with the Oculus Go virtual reality viewer, a device with CE obligation. The program consists of 12 weeks of individual training, delivered twice weekly in 45-minute sessions in a controlled setting, from T0 (baseline) to T1 (3 months after T0). |
|
アクティブコンパレータ：Participants with diagnosis of schizophrenia receiving standard clinical care
Participants receiving standard clinical care, including pharmacological treatment and case management
|
Standard clinical care including pharmacological treatment and case management according to routine clinical practice.
|
|
実験的：Participants with diagnosis of bipolar disorder receiving VRCR
|
Participants in the VRCR group will receive individualized cognitive training using the CEREBRUM platform (IDEGO, Rome, Italy). CEREBRUM is an immersive virtual reality software where the user wearing the viewer sees a virtual environment that can be explored at 360°; it consists of 52 ecologically valid exercises of varying difficulty: 22 belonging to the Memory, and Learning Module, 10 to the Cognitive Estimates Module and 20 to the Attention and Working Memory Module. The difficulty of exercises is adaptable to provide adequately implement scaffolding and errorless learning principles, and the exercises require active interaction with the therapist. The software is compatible with the Oculus Go virtual reality viewer, a device with CE obligation. The program consists of 12 weeks of individual training, delivered twice weekly in 45-minute sessions in a controlled setting, from T0 (baseline) to T1 (3 months after T0). |
|
アクティブコンパレータ：Participants with diagnosis of bipolar disorder receiving standard clinical care
Participants receiving standard clinical care, including pharmacological treatment and case management
|
Standard clinical care including pharmacological treatment and case management according to routine clinical practice.
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in cognitive performance measured by MATRICS Consensus Cognitive Battery (MCCB) total score
時間枠：Baseline, 3 months (end of the intervention), and 6 months
|
Cognitive performance will be assessed using the MATRICS Consensus Cognitive Battery (MCCB), a standardized neuropsychological battery evaluating processing speed, attention/vigilance, working memory, verbal learning, visual learning, reasoning/problem solving, and social cognition.
|
Baseline, 3 months (end of the intervention), and 6 months
|
|
Change in psychosocial functioning measured by Personal and Social Performance (PSP) scale
時間枠：Baseline, 3 months (end of the intervention), and 6 months
|
Psychosocial functioning will be assessed using the Personal and Social Performance (PSP) scale, which evaluates socially useful activities, personal and social relationships, self-care, and disturbing or aggressive behaviors.
|
Baseline, 3 months (end of the intervention), and 6 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Clinical Global Impression (CGI) severity score
時間枠：Baseline, 3 months (end of the intervention), and 6 months
|
Baseline, 3 months (end of the intervention), and 6 months
|
|
|
Change in Positive and Negative Syndrome Scale (PANSS) total score in participants with schizophrenia spectrum disorders
時間枠：Baseline, 3 months (end of the intervention), and 6 months
|
Baseline, 3 months (end of the intervention), and 6 months
|
|
|
Change in Brief Negative Symptom Scale (BNSS) total score in participants with schizophrenia spectrum disorders
時間枠：Baseline, 3 months (end of the intervention), and 6 months
|
Baseline, 3 months (end of the intervention), and 6 months
|
|
|
Change in Hamilton Depression Rating Scale (HAM-D) total score in participants with bipolar disorder
時間枠：Baseline, 3 months (end of the intervention), and 6 months
|
Baseline, 3 months (end of the intervention), and 6 months
|
|
|
Change in Young Mania Rating Scale (YMRS) total score in participants with bipolar disorder
時間枠：Baseline, 3 months (end of the intervention), and 6 months
|
Baseline, 3 months (end of the intervention), and 6 months
|
|
|
Neurobiological correlates assessed by functional magnetic resonance imaging (fMRI) in patients with a diagnosis of SSD
時間枠：Baseline
|
Baseline
|
|
|
Changes in neuroplasticity-related biomarkers (BDNF, VEGF, DYRK1A)
時間枠：Baseline to 3 months (end of the intervention)
|
Blood samples will be analyzed to assess biomarkers associated with neuroplasticity and cognitive functioning in patients with SSD and BD.
|
Baseline to 3 months (end of the intervention)
|
協力者と研究者
捜査官
- スタディチェア：Antonio Vita, MD, PhD、Università degli Studi di Brescia
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- FULL-MINDSET
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。